A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Thomas VanasscheM M EngelenQ Van ThilloJ WautersJ GunstC WoutersC VandenbrieleS RexL LiesenborghsA WilmerP MeerssemanG Van den BergheD DauweG VerbekeM ThomeerT FivezD MesottenD RuttensL HeytensI DapperS TuylsB De TavernierP Verhammenull nullPublished in: Trials (2020)
The EU Clinical Trials Register 2020-001739-28 . Registered on April 10, 2020.